Zhao Xiaogang, Sun Qifeng, Tian Hui, Cong Bo, Jiang Xingtao, Peng Chuanliang
Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
Asian Pac J Cancer Prev. 2011;12(10):2741-5.
The loss or downregulation of human leukocyte antigen ( HLA-I) has been proposed to contribute to immune evasion by cancer cells. Since the human leukocyte antigen (HLA-I) complex is located at 6p21.3, loss of heterozygosity of this region may alter HLA class I tumor phenotypes. The aim of this study was to analysis loss of heterozygosity (LOH) of chromosome 6p in ESCC samples and correlate this with HLA class I expression.
A total of 87 formalin-fixed, paraffin-embeded and frozen-fresh of ECSS lesions were collected. HLA-Iand antigen-processing machinery component expression was investigated by immunohistochemistry with anti-HLA class I monoclonal antibody and a panel of 49 ESCCs with downregulated HLA class I expression were selected for LOH studies using 3 microsatellite markers located at 6p21.3 (D6S105,D6S265,D6S273).
HLA-Iantigen,TAP1 and LMP were lost or down-regulated in 57.5, 29.8 and 47.0% of the ESCC lesions, respectively. In 23/49(46.9%) of the ESCCs, allelic loss for at least one locus at 6p21.3 was found.
Our data show that downregulation of HLA class I expression is correlated with loss of heterozygosity regions at 6p21.3 in ESCC.
已有研究提出人类白细胞抗原(HLA-I)的缺失或下调有助于癌细胞逃避免疫。由于人类白细胞抗原(HLA-I)复合体位于6p21.3,该区域杂合性缺失可能会改变HLA I类肿瘤表型。本研究的目的是分析食管鳞状细胞癌(ESCC)样本中6号染色体p臂的杂合性缺失(LOH)情况,并将其与HLA I类表达相关联。
共收集了87例经福尔马林固定、石蜡包埋以及冷冻新鲜的ESCC病变样本。采用抗HLA I类单克隆抗体通过免疫组织化学法研究HLA-I及抗原加工机制成分的表达,并使用位于6p21.3的3个微卫星标记(D6S105、D6S265、D6S273),选择49例HLA I类表达下调的ESCC进行LOH研究。
在ESCC病变中,HLA-I抗原、TAP1和LMP的缺失或下调分别占57.5%、29.8%和47.0%。在49例ESCC中的23例(46.9%)中,发现6p21.3至少一个位点存在等位基因缺失。
我们的数据表明,ESCC中HLA I类表达下调与6p21.3杂合性缺失区域相关。